# US 2003/0232809 A1 · Lipid-rich plaque inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0232809 A1
- Document ID: US20030232809A1
- Status: Published application
- Kind: A1
- Application number: 10/332,632
- Filed: 2003-01-10
- Published: 2003-12-18
- Earliest claimed: 2000-07-13
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Zen-ichi Terashita; Masahira Nakamura; Shogo Marui; Masaki Ogino
- Web page: https://patentgrep.com/patent/US20030232809A1

## CPC

- C07D 307/82: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 307/93: condensed with a ring other than six-membered
- C07D 311/16: substituted in position 7
- C07D 311/18: substituted otherwise than in position 3 or 7
- C07D 311/94: condensed with rings other than six-membered or with ring systems containing such rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 493/04: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a lipid-rich plaque regressing agent comprising a compound represented by Formula: 1 in which ring A is a cyclic hydrocarbon or the like; ring B is a heterocyclic ring or the like; each of X and Y is —NR1— (in which R1 is a hydrocarbon or the like); D is a C1-3 alkylene group or the like; E is —NH— or the like; G is a bond or the like; and Ar is an aryl or the like; D may be taken together with a constituent atom of the ring B to form a ring, and R4 may be taken together with a constituent atom of the ring B to form a ring.

## Claims

### Claim 1

A lipid-rich plaque regressing agent comprising a compound represented by Formula [I]:
189
in which ring A is an optionally substituted cyclic hydrocarbon or an optionally substituted heterocyclic ring; ring B is a 5- or 6-membered homocyclic or heterocyclic ring; each of X and Y is —NR1— (in which R1 is a hydrogen atom, optionally substituted hydrocarbon group, optionally substituted hydroxyl group or optionally substituted amino group), —O—, —S—, —CO—, —CS—, —C(R2)R2a— (in which each of R2 and R2a is a hydrogen atom, optionally substituted hydroxyl group or optionally substituted hydrocarbon group), —N═ or ═CR3— (in which R3 is a hydrogen atom, halogen atom, optionally substituted hydrocarbon group, optionally substituted hydroxyl group, or a mercapto group which may be substituted by an optionally substituted hydrocarbon group); D is a C1-3 alkylene group which may be substituted by an oxo group or thioxo group, —NH— or —CH2NH—; E is —NR4— (in which R4 is a hydrogen atom or optionally substituted hydrocarbon group), —O—, —S(O)n- (n is 0, 1 or 2) or —CONR5— (in which R5 is a hydrogen atom or optionally substituted hydrocarbon group); G is a bond or C1-3 alkylene group; Ar is an optionally substituted aryl group or optionally substituted heterocyclic group, D may be taken together with a constituent atom of the ring B to form a 5-to 7-membered ring which may be substituted by an oxo group or thioxo group, R4 may be taken together with a constituent atom of the ring B to form a 5- to 7-membered ring which may be substituted by an oxo group or thioxo group, and the ring B may have a further substituent in addition to -D-E-G-Ar or a salt thereof.

### Claim 2 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 comprising a compound represented by Formula [II]:
190
in which ring A′ is an optionally substituted 6-membered cyclic hydrocarbon group; ring C is an optionally substituted benzene ring; one of X′ and Z is —NR1′— (in which R1′ is a hydrogen atom, optionally substituted hydrocarbon group or optionally substituted amino group), —O— or —S— and the other is —CO—, —CS— or —C(R2′)R2a′— (in which each of R2′ and R2a′ is a hydrogen atom or optionally substituted hydrocarbon group), or one of them is —N═ and the other is ═CR3′— (in which R3′ is a hydrogen atom, halogen atom, optionally substituted hydrocarbon group, optionally substituted amino group, optionally substituted hydroxyl group or a mercapto group which may be substituted by an optionally substituted hydrocarbon group);
191
is a single bond or double bond; Y′, when
192
adjacent to Y′ is a single bond, is
193
(in which R6 is a hydrogen atom, hydroxyl group or optionally substituted hydrocarbon group) or a nitrogen atom, Y′, when
194
adjacent to Y′ is a double bond, is a carbon atom; D′ is a C1-3 alkylene group which may be substituted by an oxo group or thioxo group; E′ is —NR7— (in which R7 is a hydrogen atom or optionally substituted hydrocarbon group), —O— or —S(O)n- (in which n is 0, 1 or 2); G′ is a bond or C1-3 alkylene group; Ar′ is an optionally substituted aryl group or optionally substituted heterocyclic group, D′ may be taken together with Z to form a 5- to 7-membered ring which may be substituted by an oxo group or thioxo group, R7 may be taken together with Z to form a 5- to 7-membered ring which may be substituted by an oxo group or thioxo group, or a salt thereof.

### Claim 3 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 comprising a compound represented by Formula [III]:
195
in which each of ring A″, ring C′ and ring D is an optionally substituted benzene ring, X″ is —NR8— (in which R8 is a hydrogen atom or optionally substituted hydrocarbon group), —O— or —S—, U is —(CH2)m- (in which m is 1 or 2) or —NH—, Ra is a hydrogen atom or optionally substituted hydrocarbon group), or a salt thereof.

### Claim 4 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 comprising a compound represented by Formula [IV]:
196
in which ring A′″ is an optionally substituted benzene ring, Q is an optionally substituted aromatic ring, W is —CH2—, —CO— or —CS—, V is
197
or W and V are taken together to form
198
Y″ is —CH2—, —O—, —S—, —CO—, —CS— or —NR9 (in which R9 is a hydrogen atom or hydrocarbon group), U′ is —NH—, —CH2— or —CH2NH—, Rb is a hydrogen atom or optionally substituted hydrocarbon group,
199
is a single bond or double bond, or a salt thereof.

### Claim 5 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 comprising a compound represented by Formula [V]:
200
in which each of R10 and R11 is a hydrogen atom, halogen atom, optionally substituted linear hydrocarbon group, or hydroxyl group which may be substituted by an optionally substituted linear hydrocarbon group, or the both may be taken together with the adjacent carbon atoms to form an optionally substituted cyclic hydrocarbon or a dihydrofuran ring which may be substituted by an oxo group, ring I is an optionally substituted benzene ring or optionally substituted pyridine ring, ring J is an optionally substituted benzene ring or optionally substituted pyridine ring, or a salt thereof.

### Claim 6 (depends on 5)

The lipid-rich plaque regressing agent according to claim 5 wherein each of R10 and R11 is a hydrogen atom, halogen atom or optionally substituted linear hydrocarbon group, or the both may be taken together with the adjacent carbon atoms to form an optionally substituted cyclic hydrocarbon.

### Claim 7 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 comprising a compound represented by Formula [VI]:
201
in which each of R12 and R13 is a hydrogen atom, halogen atom or optionally substituted linear hydrocarbon group, or the both may be taken together with the adjacent carbon atoms to form an optionally substituted cyclic hydrocarbon,
202
is an optionally substituted phenyl group, and ring L is an optionally substituted benzene ring or optionally substituted pyridine ring, or a salt thereof.

### Claim 8 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 which is a prophylactic and therapeutic agent against acute coronary artery syndrome.

### Claim 9 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 which is a prophylactic and therapeutic agent against acute myocardial infarction.

### Claim 10 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 which is a prophylactic and therapeutic agent against unstable angina.

### Claim 11 (depends on 1)

The lipid-rich plaque regressing agent according to claim 1 which is a prophylactic and therapeutic agent against peripheral artery occlusion.

### Claim 12

A compound represented by Formula [V]:
203
in which each of R10 and R11 is a hydrogen atom, halogen atom, optionally substituted linear hydrocarbon group, or hydroxyl group which may be substituted by an optionally substituted linear hydrocarbon group, or the both may be taken together with the adjacent carbon atoms to form an optionally substituted cyclic hydrocarbon or a dihydrofuran ring which may be substituted by an oxo group, ring I is an optionally substituted benzene ring or optionally substituted pyridine ring, ring J is an optionally substituted benzene ring or optionally substituted pyridine ring, provided that when R10 is a hydrogen atom, then R11 is an optionally substituted linear hydrocarbon group, or a salt thereof.

### Claim 13 (depends on 12)

The compound according to claim 12 wherein each of R10 and R11 is a hydrogen atom, halogen atom or optionally substituted linear hydrocarbon group, or the both are taken together with the adjacent carbon atoms to form an optionally substituted cyclic hydrocarbon.

### Claim 14 (depends on 12)

The compound according to claim 12 wherein each of R10 and R11 is a halogen atom or optionally substituted C1-7 alkyl group.

### Claim 15 (depends on 12)

The compound according to claim 12 wherein the cyclic hydrocarbon is a C5-7 cyclic hydrocarbon.

### Claim 16 (depends on 12)

The compound according to claim 12 wherein the ring J is a benzene ring substituted by halogenated alkyl group and/or halogen atom.

### Claim 17 (depends on 12)

The compound according to claim 12 wherein the ring I is a benzene ring which may be substituted by alkyl group, halogenated alkyl group or halogen atom.

### Claim 18

A compound represented by Formula [VI]:
204
in which each of R12 and R13 is a hydrogen atom, halogen atom or optionally substituted linear hydrocarbon group, or the both may be taken together with the adjacent carbon atoms to form an optionally substituted cyclic hydrocarbon,
205
is an optionally substituted phenyl group (provided that 2-chlorophenyl and 2-fluorophenyl are excluded), and ring L is an optionally substituted benzene ring or optionally substituted pyridine ring, provided that when
206
is a phenyl group, then R13 is not a methyl group, and when
207
is a 2-methylphenyl group, then R13 is not a chlorine atom, or a salt thereof.

### Claim 19 (depends on 18)

The compound according to claim 18 wherein each of R12 and R13 is a halogen atom or C1-3 alkyl group.

### Claim 20 (depends on 18)

The compound according to claim 18 wherein the cyclic hydrocarbon is a C5-7 cyclic hydrocarbon.

### Claim 21 (depends on 18)

The compound according to claim 18 wherein
208
is a phenyl group which may be substituted by a C1-3 alkyl group.

### Claim 22 (depends on 18)

The compound according to claim 18 wherein the ring L is a substituted benzene ring.

### Claim 23

2-[7-Chloro-4-(3-chlorophenyl)-6-methyl-2-oxo-2H-chromen-3-yl]-N-[4-chloro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-4-(3-chlorophenyl)-6-methyl-2-oxo-2H-chromen-3-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-4-(3-chloro-4-fluorophenyl)-6-methyl-2-oxo-2H-chromen-3-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-4-(3-chloro-4-fluorophenyl)-6-methyl-2-oxo-2H-chromen-3-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-6-methyl-4-(3-methylphenyl)-2-oxo-2H-chromen-3-yl]-N-[4-chloro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-6-methyl-4-(3-methylphenyl)-2-oxo-2H-chromen-3-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-2-oxo-4-phenyl-6-[(4-phenylpiperazin-1-yl)methyl]-2H-chromen-3-yl]-N-[4-chloro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-2-oxo-4-phenyl-6-[(4-phenylpiperazin-1-yl)methyl]-2H-chromen-3-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-6-[[4-(4-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl]methyl]-2-oxo-4-phenyl-2H-chromen-3-yl]-N-[4-chloro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-6-[[4-(4-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl]methyl]-2-oxo-4-phenyl-2H-chromen-3-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-6-[[4-(3-methylphenyl)piperidin-1-yl]methyl]-2-oxo-4-phenyl-2H-chromen-3-yl]-N-[4-chloro-2-(trifluoromethyl)phenyl]acetamide; 2-[7-chloro-6-[[4-(3-methylphenyl)piperidin-1-yl]methyl]-2-oxo-4-phenyl-2H-chromen-3-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]acetamide; or a salt thereof.

### Claim 24 (depends on 12, 18, 23)

A prodrug of a compound according to any one of claim 12, 18 or 23.

### Claim 25 (depends on 12, 18, 23)

A pharmaceutical composition comprising a compound according to any one of claim 12, 18 or 23 or a prodrug thereof.

### Claim 26

An agent for inhibiting progression of an arteriosclerotic focus comprising a compound having a lipid-rich plaque regressing effect or a salt thereof.

### Claim 27 (depends on 26)

The agent according to claim 26 in combination with an HMG-CoA reductase inhibitor.

### Claim 28 (depends on 12)

A method for producing the compound according to claim 12 or a salt thereof, which comprises reacting a compound represented by Formula [VII]:
209
[in which each symbol is as defined in claim 12] or a salt thereof or a reactive derivative thereof with a compound represented by Formula [VIII]:
210
[in which each symbol is as defined in claim 12] or a salt thereof.

### Claim 29 (depends on 18)

A method for producing the compound according to claim 18 or a salt thereof, which comprises reacting a compound represented by Formula [IX]:
211
[in which each symbol is as defined in claim 18] or a salt thereof or a reactive derivative thereof with a compound represented by Formula [X]:
212
[in which each symbol is as defined in claim 18] or a salt thereof.

### Claim 30 (depends on 18)

A method for producing the compound according to claim 18 or a salt thereof, which comprises reacting a compound represented by Formula [XI]:
213
[in which each symbol is as defined in claim 18] or a salt thereof with a compound represented by Formula [XII]:
214
[in which each symbol is as defined in claim 18] or a salt thereof.

### Claim 31 (depends on 1)

A method for regressing a lipid-rich plaque in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a salt thereof to a mammal.

### Claim 32 (depends on 1)

A method for preventing and treating acute coronary artery syndrome in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a salt thereof to a mammal.

### Claim 33 (depends on 1)

A method for preventing and treating acute myocardial infarction in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a salt thereof to a mammal.

### Claim 34 (depends on 1)

A method for preventing and treating unstable angina in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a salt thereof to a mammal.

### Claim 35 (depends on 1)

A method for preventing and treating peripheral artery occlusion in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a salt thereof to a mammal.

### Claim 36 (depends on 12)

A method for regressing a lipid-rich plaque in a mammal, which comprises administering an effective amount of the compound according to claim 12, a salt thereof or a prodrug thereof to a mammal.

### Claim 37 (depends on 18)

A method for regressing a lipid-rich plaque in a mammal, which comprises administering an effective amount of the compound according to claim 18, a salt thereof or a prodrug thereof to a mammal.

### Claim 38 (depends on 1)

A use of the compound according to claim 1 or a salt thereof for producing a lipid-rich plaque regressing agent.

### Claim 39 (depends on 1)

A use of the compound according to claim 1 or a salt thereof for producing a prophylactic and therapeutic agent against acute coronary artery syndrome.

### Claim 40 (depends on 1)

A use of the compound according to claim 1 or a salt thereof for producing a prophylactic and therapeutic agent against acute myocardial infarction.

### Claim 41 (depends on 1)

A use of the compound according to claim 1 or a salt thereof for producing a prophylactic and therapeutic agent against unstable angina.

### Claim 42 (depends on 1)

A use of the compound according to claim 1 or a salt thereof for producing a prophylactic and therapeutic agent against peripheral artery occlusion.

### Claim 43 (depends on 12)

A use of the compound according to claim 12, a salt thereof or a prodrug thereof for producing a lipid-rich plaque regressing agent.

### Claim 44 (depends on 18)

A use of the compound according to claim 18, a salt thereof or a prodrug thereof for producing a lipid-rich plaque regressing agent.
